Disease kinetics and practice patterns in ≥ 4-year long-term beneficiaries of immune checkpoint inhibitors for advanced non–small cell lung cancer.

8561 Background: Immune checkpoint inhibitors (ICIs) have transformed outcomes in advanced non-small cell lung cancer (NSCLC), enabling durable responses in a subset of patients (pts). However, detailed clinical trajectories and patterns of late disease progression among long-term survivors remain poorly characterized. Methods: This multicenter retrospective cohort study enrolled advanced NSCLC pts who initiated ICI-containing therapy between January 2015 and April 2020. Long-term beneficiaries